Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70198 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Derek Z Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer, Inc., San Diego, CA, USA. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Dabigatran, Pyrimidines, Sulfonamides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer, Inc., Arvinas Estrogen Receptor, Inc..
Abstract (Originalsprache)
Aims
To evaluate the effects of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) oestrogen receptor degrader, on the pharmacokinetics of dabigatran (a P‐glycoprotein [P‐gp] substrate) and rosuvastatin (a breast cancer resistance protein [BCRP] substrate).
Methods
In two phase 1, open‐label, two‐period, fixed‐sequence studies, healthy adult participants received a single oral dose of dabigatran etexilate 75 mg or rosuvastatin 10 mg alone and with a single dose of vepdegestrant 200 mg. Serial plasma samples were collected after dosing, and pharmacokinetic parameters for dabigatran and rosuvastatin were estimated by standard noncompartmental analysis.
Results
Coadministration of the P‐gp substrate dabigatran etexilate with vepdegestrant increased dabigatran area under the concentration–time curve (AUC) from time 0 to infinity by 98% and maximum plasma concentration ( C max ) by 92%. Coadministration of the BCRP substrate rosuvastatin with vepdegestrant increased rosuvastatin plasma AUC from time 0 to time of the last measurable concentration by 11% and C max by 21%.
Conclusions
Coadministration with vepdegestrant doubled dabigatran exposure and resulted in a minor increase (11%) in rosuvastatin exposure in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer, Inc., San Diego, CA, USA.
- Pfizer, Inc., Groton, CT, USA.
- Pfizer, Inc., Collegeville, PA, USA.
- Pfizer, Inc., Brussels, Belgium.
- Pfizer, Inc., New Haven, CT, USA.
- Pfizer, Inc., Beijing, China.
ORCID-Profile: Weiwei Tan
Förderung
- Pfizer, Inc.
- Arvinas Estrogen Receptor, Inc.
Zitieren
APA
Yang, D. Z., Zhou, L., Winton, J. A., Matschke, K. T., Kantaridis, C., Doyle, K., Lee, K. C., Chen, N., Zhang, Y., & Tan, W. (2025). Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70198
Vancouver
Yang DZ, Zhou L, Winton JA, Matschke KT, Kantaridis C, Doyle K, et al. Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70198
BibTeX
@article{Yang2025,
author = {Yang, Derek Z and Zhou, Li and Winton, Jennifer A and Matschke, Kyle T and Kantaridis, Constantino and Doyle, Kristine and Lee, Kimberly C and Chen, Naihan and Zhang, Yuanyuan and Tan, Weiwei},
title = {Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70198}
}
EUVIMED